India, Aug. 19 -- Twist Bioscience Corporation (TWST), a biotechnology company providing DNA synthesis, protein solutions and next-generation sequencing (NGS) tools, recently reported strong fiscal third-quarter 2026 financial results, highlighted by record revenue, improving gross margins and continued sequential growth.
The company generated record revenue of $118.4 million in the third quarter of fiscal 2026, up more than 23% from $96.1 million in the year-ago quarter, marking its 14th consecutive quarter of sequential growth.
Financial Performance
Twist's DNA Synthesis and Protein Solutions (DSPS) revenue increased 39% to $56.6 million, compared with $40.8 million in the third quarter of fiscal 2025.
NGS Applications revenue grew 12...